Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of theLEADERandSUSTAIN6 trials

被引:48
作者
Verma, Subodh [1 ]
McGuire, Darren K. [3 ]
Bain, Stephen C. [4 ]
Bhatt, Deepak L. [5 ,6 ]
Leiter, Lawrence A. [1 ,2 ]
Mazer, C. David [1 ,2 ]
Monk Fries, Tea [7 ]
Pratley, Richard E. [8 ]
Rasmussen, Soren [7 ]
Vrazic, Hrvoje [7 ]
Zinman, Bernard [9 ]
Buse, John B. [10 ]
机构
[1] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Texas Southwestern Med Ctr Dallas, Div Cardiol, Dallas, TX 75390 USA
[4] Swansea Univ, Inst Life Sci, Swansea, W Glam, Wales
[5] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA
[6] Harvard Med Sch, Boston, MA 02115 USA
[7] Novo Nordisk AS, Soborg, Denmark
[8] AdventHlth Translat Res Inst, Orlando, FL USA
[9] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[10] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
关键词
body mass index; cardiovascular; liraglutide; major adverse cardiovascular events; semaglutide;
D O I
10.1111/dom.14160
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Associations between body mass index (BMI) and the cardiovascular (CV) and kidney efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) are uncertain; therefore, data analysed separately from the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial and the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN 6) were examined. These international, randomized, placebo-controlled trials investigated liraglutide and semaglutide (both subcutaneous) in patients with T2D and at high risk of CV events. In post hoc analyses, patients were categorized by baseline BMI (<25, >= 25-<30, >= 30-<35 and >= 35 kg/m(2)), and CV and kidney outcomes with GLP-1 RA versus placebo were analysed. All baseline BMI data from LEADER (n = 9331) and SUSTAIN 6 (n = 3290) were included (91% and 92% of patients with overweight or obesity, respectively). In SUSTAIN 6, nominally significant heterogeneity of semaglutide efficacy by baseline BMI was observed for CV death/myocardial infarction/stroke (major adverse CV events, primary outcome of both;P-interaction= .02); otherwise, there was no statistical heterogeneity for either GLP-1 RA versus placebo across BMI categories for key CV and kidney outcomes. The lack of statistical heterogeneity from these cardiorenal outcomes implies that liraglutide and semaglutide may be beneficial for many patients and is probable not to depend on their baseline BMI, but further study is needed.
引用
收藏
页码:2487 / 2492
页数:6
相关论文
共 17 条
  • [2] Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
    Buse, John B.
    Bain, Stephen C.
    Mann, Johannes F. E.
    Nauck, Michael A.
    Nissen, Steven E.
    Pocock, Stuart
    Poulter, Neil R.
    Pratley, Richard E.
    Linder, Martin
    Monk Fries, Tea
    Orsted, David D.
    Zinman, Bernard
    [J]. DIABETES CARE, 2020, 43 (07) : 1546 - 1552
  • [3] Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis
    Cai, Xiaoling
    Yang, Wenjia
    Gao, Xueying
    Zhou, Lingli
    Han, Xueyao
    Ji, Linong
    [J]. PLOS ONE, 2016, 11 (12):
  • [4] Clinical Effectiveness of Liraglutide Across Body Mass Index in Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study
    Chitnis, Abhishek S.
    Ganz, Michael L.
    Benjamin, Nicole
    Langer, Jakob
    Hammer, Mette
    [J]. ADVANCES IN THERAPY, 2014, 31 (09) : 986 - 999
  • [5] The Look AHEAD Trial: Implications for Lifestyle Intervention in Type 2 Diabetes Mellitus
    Dutton, Gareth R.
    Lewis, Cora E.
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 2015, 58 (01) : 69 - 75
  • [6] Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
    Gerstein, Hertzel C.
    Colhoun, Helen M.
    Dagenais, Gilles R.
    Diaz, Rafael
    Lakshmanan, Mark
    Pais, Prem
    Probstfield, Jeffrey
    Riesmeyer, Jeffrey S.
    Riddle, Matthew C.
    Ryden, Lars
    Xavier, Denis
    Atisso, Charles Messan
    Dyal, Leanne
    Hall, Stephanie
    Rao-Melacini, Purnima
    Wong, Gloria
    Avezum, Alvaro
    Basile, Jan
    Chung, Namsik
    Conget, Ignacio
    Cushman, William C.
    Franek, Edward
    Hancu, Nicolae
    Hanefeld, Markolf
    Holt, Shaun
    Jansky, Petr
    Keltai, Matyas
    Lanas, Fernando
    Leiter, Lawrence A.
    Lopez-Jaramillo, Patricio
    Cardona Munoz, Ernesto German
    Pirags, Valdis
    Pogosova, Nana
    Raubenheimer, Peter J.
    Shaw, Jonathan E.
    Sheu, Wayne H-H
    Temelkova-Kurktschiev, Theodora
    [J]. LANCET, 2019, 394 (10193) : 121 - 130
  • [7] Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
    Hernandez, Adrian F.
    Green, Jennifer B.
    Janmohamed, Salim
    D'Agostino, Ralph B., Sr.
    Granger, Christopher B.
    Jones, Nigel P.
    Leiter, Lawrence A.
    Rosenberg, Anne E.
    Sigmon, Kristina N.
    Somerville, Matthew C.
    Thorpe, Karl M.
    McMurray, John J. V.
    Del Prato, Stefano
    [J]. LANCET, 2018, 392 (10157) : 1519 - 1529
  • [8] Liraglutide and Renal Outcomes in Type 2 Diabetes
    Mann, Johannes F. E.
    Orsted, David D.
    Brown-Frandsen, Kirstine
    Marso, Steven P.
    Poulter, Neil R.
    Rasmussen, Soren
    Tornoe, Karen
    Zinman, Bernard
    Buse, John B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09) : 839 - 848
  • [9] Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Marso, Steven P.
    Daniels, Gilbert H.
    Brown-Frandsen, Kirstine
    Kristensen, Peter
    Mann, Johannes F. E.
    Nauck, Michael A.
    Nissen, Steven E.
    Pocock, Stuart
    Poulter, Neil R.
    Ravn, Lasse S.
    Steinberg, William M.
    Stockner, Mette
    Zinman, Bernard
    Bergenstal, Richard M.
    Buse, John B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04) : 311 - 322
  • [10] multicenter collaboration group of Department of S Technology of Guangdong P Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus p, 2020, ZHONGHUA JIE HE HE H, V43, pE019